euro adhoc: Marseille-Kliniken AG / Quarterly or Semiannual Financial Statements / - 5 % increase in sales to EUR 150.3 million in the first three quarters

- Overall earnings of EUR 6.2 million slowed down due to macro-economic impacts in Rehabilitation

- Full-year earnings expected to improve on the previous year (E)=

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

In the first three quarters of the fiscal year 2003/04, the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to further increase sales by 5.0% to EUR 150.3 million (previous year EUR 143.2 million). The earnings pursuant to DVFA/SG (IFRS) amounted to EUR 6.2 million compared with EUR 6.3 million in the previous year. The earnings per share came to EUR 0.51 following EUR 0.52 in the same period one year ago. Thus, for the most part the once again positive earnings trend in the Nursing division was able to offset the macro-economically and the seasonally impacted result in the Rehabilitation division in the 3rd quarter.

The occupancy rate in the entire Group amounted to 89.8% for the reference period compared with 92.3% one year ago. Besides the still low occupancy rate in the Rehabilitation division, the main reasons are four start-up facilities and four acquired facilities in the Nursing division in the previous fiscal year.

In its core segment Nursing, in which Marseille-Kliniken provides three quarters of the Group’s total bed capacity, sales and earnings continued to improve considerably. With sales of EUR 108.3 million in this segment during the period under review, Marseille-Kliniken realized a rise in sales of EUR 11 million with respect to the EUR 97.3 million sales generated in the same period one year ago. The earnings pursuant to DVFA/SG (IFRS) were improved to EUR 8.6 million, up EUR 0.8 million from EUR 7.8 million.

In the Rehabilitation division a trend reversal with respect to the occupancy rate could not yet be experienced in the 3rd quarter of the current fiscal year. In particular in the psychosomatic unit, which accounts for 40% of the total capacities in the Rehabilitation segment, the cyclically-related decline in the occupancy rate in the 3rd quarter was disproportionately high. Accordingly, sales remained EUR 3.9 million below previous year’s level of EUR 45.9 million and amounted to EUR 42.0 million in the first nine months of the fiscal year 2003/04. Compared with the previous year, the earnings pursuant to DVFA/SG (IFRS) weakened by EUR -0.9 million to EUR -2.4 million (previous year EUR -1.5 million).

Due to seasonal effects and additional cost-reduction measures, we expect improved results in the Rehabilitation division in the 4th quarter and all in all reaffirm our forecast for the full-year to achieve a 7% rise in sales and a disproportionate increase in earnings.

Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
Alte Jakobstraße 79/80
10709 Berlin
Tel.: 030 / 246 32-400
Fax: 030 / 246 32-401
Christian Hillermann
Managing Director Haubrok IR
Tel: +49(0) 40 51459 0
FAX: +49(0) 40 51459 737

Emittent: Marseille-Kliniken AG Sportallee 1 DE-22335 Hamburg Tel: +49(0) 40 51459 0 FAX: +49(0) 40 51459 737 Email: WWW: ISIN: DE0007783003 WKN: 778300 Indizes: CDAX, Classic All Share, Prime All Share, Prime Standard Börsen: official dealing Hamburger Wertpapierbörse, Frankfurter

end of announcement euro adhoc

Wertpapierbörse; free trade Berliner Wertpapierbörse, Bremer Wertpapierbörse (BWB), Börse Düsseldorf, Baden-Württembergische Wertpapierbörse
Branche: Pharmaceuticals
Sprache: Englisch